Zhitong Finance App News, Nuochengjianhua (09969.HK) announced that the National Drug Administration (NMPA) has approved the second-generation small-molecule pantogen myosin kinase inhibitor (pan-TRK inhibitor) zoletrantinib (ICP-723) for the treatment of adults carrying the NTRK fusion gene and adolescent solid cancer patients aged 12 and over.

Zhitong Finance App News, Nuochengjianhua (09969.HK) announced that the National Drug Administration (NMPA) has approved the second-generation small-molecule pantogen myosin kinase inhibitor (pan-TRK inhibitor) zoletrantinib (ICP-723) for the treatment of adults carrying the NTRK fusion gene and adolescent solid cancer patients aged 12 and over.